[Intra-articular therapy with autologous interleukin-1 receptor antagonist in osteoarthritis. Innovation or quackery?].
Stengel
D
D
Fachbereich Klinische Epidemiologie, Klinik für Unfall- und Wiederherstellungschirurgie, Unfallkrankenhaus, Berlin. dirk.stengel@ukb.de
Ekkernkamp
A
A
Wich
M
M
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001685:Biological Factors / Q000009:adverse effects / Q000627:therapeutic use*; D001781:Blood Component Removal; D005500:Follow-Up Studies; D006801:Humans; D007270:Injections, Intra-Articular; D007375:Interleukin-1 / Q000097:blood; D010003:Osteoarthritis / Q000276:immunology / Q000628:therapy*; D011781:Quackery; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors* / Q000097:blood; D015203:Reproducibility of Results; D013585:Synovitis / Q000188:drug therapy / Q000276:immunology; D016896:Treatment Outcome; D014221:Triamcinolone / Q000009:adverse effects / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D001685:Biological Factors; D007375:Interleukin-1; D017472:Receptors, Interleukin-1; D014221:Triamcinolone